Evaluation of long-term efficacy outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response.

Medical records of patients that previously underwent the Alpha DaRT treatment will be reviewed by an authorized staff member.

Evaluation of long-term outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response. These outcomes include:

• Safety - assessment of late onset of Alpha DaRT related AE in patients treated with the Alpha DaRT seeds

• Efficacy -

  • assessment of local recurrence rates in patients who achieved initial complete response (CR) following the Alpha DaRT treatment
  • assessment of duration of response in patients who achieved initial CR following the Alpha DaRT treatment
  • assessment of survival status in patients treated with the Alpha DaRT seeds

Inclusion Criteria:

• Patients previously treated with the Alpha DaRT seeds for management of either skin or oral cavity SCC
• Available information in medical charts and records (electronic or paper)

Exclusion Criteria:

None.

The medical records of patients previously treated with Alpha DaRT as part of the completed clinical trial "CTP-SCC-00" will be accessed to follow up with their status, if available.